Literature DB >> 20461477

Primary brain tumors in the elderly.

Lakshmi Nayak1, Fabio M Iwamoto.   

Abstract

The incidence of primary brain tumors is highest in elderly patients, and advanced age often is a negative prognostic factor. Nevertheless, large randomized studies in this population are scarce. Elderly patients with primary brain tumors also present unique challenges, such as the presence of multiple comorbidities and polypharmacy, decreased tolerance to chemotherapy, and an increased risk for radiation-induced neurotoxicity. This review gives an overview of the treatment options for older patients with glioblastoma and other gliomas, primary central nervous system lymphomas (PCNSLs), and meningiomas. Selected elderly glioblastoma patients with good performance status may benefit from aggressive treatment with surgical resection, radiotherapy, and possibly chemotherapy. For older patients with PCNSLs, high-dose methotrexate-based chemotherapy should be the mainstay option; whole-brain radiation therapy should be avoided in chemosensitive tumors because of the high risk of irreversible and progressive neurotoxicity. Meningiomas often may be followed up in elderly patients, as they usually are asymptomatic and have a slow growth rate. Treatment for elderly patients with primary brain tumors should be individualized, and age alone should not preclude the use of more aggressive treatments.

Entities:  

Mesh:

Year:  2010        PMID: 20461477      PMCID: PMC7398448          DOI: 10.1007/s11910-010-0110-x

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  47 in total

1.  Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.

Authors:  M L Simmons; K R Lamborn; M Takahashi; P Chen; M A Israel; M S Berger; T Godfrey; J Nigro; M Prados; S Chang; F G Barker; K Aldape
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

2.  A population-based study of glioblastoma multiforme.

Authors:  L Paszat; N Laperriere; P Groome; K Schulze; W Mackillop; E Holowaty
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-09-01       Impact factor: 7.038

3.  Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas.

Authors:  Michael Glantz; Marc Chamberlain; Qin Liu; N Scott Litofsky; Lawrence D Recht
Journal:  Cancer       Date:  2003-05-01       Impact factor: 6.860

4.  Prognosis and patterns of care in elderly patients with glioma.

Authors:  Fabio M Iwamoto; Anne S Reiner; Lakshmi Nayak; Katherine S Panageas; Elena B Elkin; Lauren E Abrey
Journal:  Cancer       Date:  2009-12-01       Impact factor: 6.860

5.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

Authors:  W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth
Journal:  J Clin Oncol       Date:  2004-03-29       Impact factor: 44.544

6.  Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients.

Authors:  Stephanie E Combs; Johanna Wagner; Marc Bischof; Thomas Welzel; Florian Wagner; Jürgen Debus; Daniela Schulz-Ertner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-10-29       Impact factor: 7.038

7.  Age as a predictive factor in glioblastomas: population-based study.

Authors:  Daisuke Kita; Ilja F Ciernik; Salvatore Vaccarella; Silvia Franceschi; Paul Kleihues; Urs M Lütolf; Hiroko Ohgaki
Journal:  Neuroepidemiology       Date:  2009-03-27       Impact factor: 3.282

8.  Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Muraya Gathinji; Frank J Attenello; Khoi Than; Alessandro Olivi; Jon D Weingart; Henry Brem; Alf Redo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2009-01       Impact factor: 5.115

9.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

10.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.

Authors:  G Minniti; V De Sanctis; R Muni; F Filippone; A Bozzao; M Valeriani; M F Osti; U De Paula; G Lanzetta; V Tombolini; R Maurizi Enrici
Journal:  J Neurooncol       Date:  2008-02-05       Impact factor: 4.130

View more
  3 in total

Review 1.  Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis.

Authors:  Saleh A Almenawer; Jetan H Badhiwala; Waleed Alhazzani; Jeffrey Greenspoon; Forough Farrokhyar; Blake Yarascavitch; Almunder Algird; Edward Kachur; Aleksa Cenic; Waseem Sharieff; Paula Klurfan; Thorsteinn Gunnarsson; Olufemi Ajani; Kesava Reddy; Sheila K Singh; Naresh K Murty
Journal:  Neuro Oncol       Date:  2015-01-03       Impact factor: 12.300

2.  Epidemiologic and histologic characteristics of CNS lesions: a 20-year experience of a tertiary center in Lebanon.

Authors:  Roland Eid; Stephanie Hage; Ingrid Antonios; Rita Moussa; Makram Khoury; Fady Ghassan Haddad; Hampig Raphael Kourie; Carole Kesrouani; Claude Ghorra; Gerard Abadjian; Joseph Kattan
Journal:  CNS Oncol       Date:  2020-06-30

Review 3.  A clinical care pathway to improve the acute care of patients with glioma.

Authors:  Natalie B V Riblet; Evelyn M Schlosser; Jennifer A Snide; Lara Ronan; Katherine Thorley; Melissa Davis; Jennifer Hong; Linda P Mason; Tobi J Cooney; Lanelle Jalowiec; Nancy L Kennedy; Sabrina Richie; David Nalepinski; Camilo E Fadul
Journal:  Neurooncol Pract       Date:  2015-10-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.